Literature DB >> 20198856

["Genes for mitochondria" in arterial hypertension and left ventricular hypertrophy].

S V Buĭkin, M V Golubenko, V P Puzyrev.   

Abstract

Study is devoted to "genes for mitochondria"--genes of mitochondrial genome and mitochondrial DNA polymerase gamma gene (POLG1). We compared frequencies of polymorphisms in mitochondrial DNA and in POLG1 between healthy individuals and patients with arterial hypertension, as well as between patients with and without left ventricular hypertrophy. We did not discover significant differences of distribution of C allele of MspI-polymorphism in POLG1 in studied group. We have shown higher prevalence of mitochondrial haplogroup H of mtDNA in patients without left ventricle hypertrophy (OR = 0.42; 95% CI 0.17-0.98; p = 0.043), while compared with patients having this complication. Haplogroup T was more frequently detected in patients with left ventricle hypertrophy (OR = 6.16; 95% CI 1.17-9.74; p = 0.018). This result suggest implication of mitochondrial DNA in hypertension-induced left venticular hypertrophy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20198856     DOI: 10.1134/s002689331001005x

Source DB:  PubMed          Journal:  Mol Biol (Mosk)        ISSN: 0026-8984


  22 in total

Review 1.  Meta- and pooled analyses of the cytochrome P-450 1B1 Val432Leu polymorphism and breast cancer: a HuGE-GSEC review.

Authors:  Valentina Paracchini; Sara Raimondi; Inger T Gram; Daehee Kang; Neslihan A Kocabas; Vessela N Kristensen; Donghui Li; Fritz F Parl; Tove Rylander-Rudqvist; Pavel Soucek; Wei Zheng; Sara Wedren; Emanuela Taioli
Journal:  Am J Epidemiol       Date:  2006-10-19       Impact factor: 4.897

2.  Specific dehydrogenation of 3-methylindole and epoxidation of naphthalene by recombinant human CYP2F1 expressed in lymphoblastoid cells.

Authors:  D L Lanza; E Code; C L Crespi; F J Gonzalez; G S Yost
Journal:  Drug Metab Dispos       Date:  1999-07       Impact factor: 3.922

Review 3.  Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers.

Authors:  H Bartsch; U Nair; A Risch; M Rojas; H Wikman; K Alexandrov
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-01       Impact factor: 4.254

4.  Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population.

Authors:  Eleni Aklillu; Mikael Oscarson; Mats Hidestrand; Brith Leidvik; Charlotta Otter; Magnus Ingelman-Sundberg
Journal:  Mol Pharmacol       Date:  2002-03       Impact factor: 4.436

Review 5.  COPD, a multicomponent disease: implications for management.

Authors:  A G N Agusti
Journal:  Respir Med       Date:  2005-01-08       Impact factor: 3.415

6.  Characterization of the human lung CYP2F1 gene and identification of a novel lung-specific binding motif.

Authors:  Brian A Carr; Jie Wan; Ronald N Hines; Garold S Yost
Journal:  J Biol Chem       Date:  2003-02-21       Impact factor: 5.157

Review 7.  Xenobiotic-metabolizing enzymes in human lung.

Authors:  Ji Y Zhang; Yuefen Wang; Chandra Prakash
Journal:  Curr Drug Metab       Date:  2006-12       Impact factor: 3.731

8.  [Association of cytochrome P450 genes polymorphisms (CYP1A1 and CYP1A2) with the development of chronic obstructive pulmonary disease in Bashkortostan].

Authors:  G F Korytina; L Z Akhmadishina; O V Kochetova; Sh Z Zagidullin; T V Viktorova
Journal:  Mol Biol (Mosk)       Date:  2008 Jan-Feb

9.  Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk.

Authors:  Lara Bethke; Emily Webb; Gabrielle Sellick; Matthew Rudd; Stephen Penegar; Laura Withey; Mobshra Qureshi; Richard Houlston
Journal:  BMC Cancer       Date:  2007-07-05       Impact factor: 4.430

10.  Leu432Val polymorphism in CYP1B1 as a susceptible factor towards predisposition to primary open-angle glaucoma.

Authors:  Ashima Bhattacharjee; Deblina Banerjee; Suddhasil Mookherjee; Moulinath Acharya; Antara Banerjee; Ananya Ray; Abhijit Sen; Kunal Ray
Journal:  Mol Vis       Date:  2008-05-08       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.